摘要:
The present invention relates to a process for the preparation of certain 1-[(heteroaryl)-methyl]-3-[4- (hydroxymethyl)-phenyl]-ureas or 1-[(aryl)-methyl]-3-[4-(hydroxymethyl)-phenyl]-ureas, in particular certain 1-[(2-aryl-2H-pyrazol-3-yl)-methyl]-3-[4-(hydroxymethyl)-phenyl]-ureas or physiologically acceptable addition salts and/or solvates thereof.
摘要:
Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.
摘要:
The present invention relates to a salicylaldehyde chiral compound (chemical formula 1) and a naphtholaldehyde chiral compound (chemical formula 2), wherein a -OH group and a carbonyl group are adjacent to each other on a benzene ring. Both compounds contain an asymmetric carbon and have relatively small molecular weight compared to that of known binaphthol derivatives. Optical transformation of amino acid and optical resolution of amino acid and aminoalcohol can be effectively carried out by the salicylaldehyde chiral compound (chemical formula 1) and naphtholaldehyde chiral compound (chemical formula 2) of the present invention.
摘要:
A compound of Formula (A) wherein Z is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl, wherein the heteroaryl or substituted heteroaryl connected to a 2,4-dinito-6-(trifluoromethyl)phenyl ring via a carbon-carbon bond.
摘要:
Novel ß1 adrenoreceptor ligands that find use as imaging agents within nuclear medicine applications (e.g., PET imaging and SPECT imaging) are provided. Methods of imaging, including methods of imaging congestive heart failure, are also provided. The novel compounds may exhibit high affinity and selectivity, minimal metabolism, minimal non-specific binding and have a favorable log P value (1-AR selective ligands are conjugated to an imaging moiety in such a way that it does not impact the antagonist affinity and their use. In other instances, the conjugation may be directly to the antagonist at several sites that will not impact affinity. In further instances, the conjugation may be by means of a linking group, which can be used to alter the pharmacokinetics and clearance of the complex.
摘要:
Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pinchinde, and VSV), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).
摘要:
The invention provides a new class of compounds capable of inhibiting carnitine palmitoyl transferase (CPT) having formula (I). The invention also relates to pharmaceutical compositions, which comprise at least one new compound according to the invention, and their therapeutic use in the treatment of hyperglycaemic conditions such as diabetes and the pathologies associated with it, such as for example congestive heart failure and obesity.
摘要:
L'invention concerne des dérivés d'acide phénoxy-isobutyrique représentés par la formule générale (I) dans laquelle; R 1 et R 2 sont H ou un groupe alkyle, ou un groupe -OR où R est un alkyle, ou R 1 et R 2 forment ensemble un cycle hydrocarboné de 3 a 6 atomes de carbone; R 3 est H ou un groupe alkyle; X et -O-, -S- ou -CH 2 -; R 4 est H, un halogène ou -CF 3' , -OCH 3' -CH 3 , -SCH 3 Y est -CH 2 CH 2 - ou -CH=CH-; Z 1 est -O- ou -NR 6 - ou R 6 est H on un groupe alkyle; Z 2 est -(C=O)-, -(C=S)- ou -(SO 2 )-; Z 3 est un groupe R 5 , -(NH-R 5 ) ou -(OR 5 ), R 5 étant un groupe cycloalkyle de 5 à 7 chaînons ou un groupe [-(CH 2 ) m -aryle], avec m = O ou 1, ou un groupe hétérocyclique. Application en thérapeutique pour le traitement du diabète de type II, des hyperlipidémies et de l'athérosclérose.